CX-4945: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 27 patients showed that oral CX-4945 produced 6 cases of stable disease. The MTD was twice-daily 1,000 mg CX-4945 given for the first 3 consecutiv...